Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide - PubMed (original) (raw)
Comparative Study
. 2008 Sep;14(9):993-1003.
doi: 10.1016/j.bbmt.2008.06.009.
Mei-Jie Zhang 2, Manza-A Agovi 2, Andrea Bacigalupo 3, Nizar J Bahlis 4, Karen Ballen 5, Christopher Brown 4, M Ahsan Chaudhry 4, Mary M Horowitz 2, Seira Kurian 6, Diana Quinlan 4, Catherine E Muehlenbien 7, James A Russell 4, Lynn Savoie 4, J Douglas Rizzo 8, Douglas A Stewart 4
Affiliations
- PMID: 18721762
- PMCID: PMC3321981
- DOI: 10.1016/j.bbmt.2008.06.009
Comparative Study
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide
Christopher N Bredeson et al. Biol Blood Marrow Transplant. 2008 Sep.
Abstract
We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG). To assess further this single-center experience, we performed a retrospective matched-pair analysis comparing outcomes of adult patients transplanted using the FluBuTG conditioning regimen with matched controls from patients reported to the CIBMTR receiving a first allogeneic hematopoietic stem cell transplant (HCT) after standard oral busulfan and cyclophosphamide (BuCy). One hundred twenty cases and 215 matched controls were available for comparison. Patients receiving FluBuTG had significantly less treatment related mortality (TRM; 12% versus 34%, P < .001) and grades II-IV aGVHD (15% versus 34%, P < .001) compared to BuCy patients. The risk of relapse was higher in the FluBuTG patients (42% versus 20%, P < .001). The risks of chronic GVHD (cGVHD) and disease free survival (DFS) were similar in the cases and controls. These results suggest that the novel regimen FluBuTG decreases the risk of aGVHD and TRM after HLA-identical sibling HSCT, but is associated with an increased risk of relapse, resulting in similar DFS. Whether these conditioning regimens may be more suitable for specific patient populations based on relapse risk requires testing in prospective randomized trials.
Similar articles
- Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Kim CK, Lee KT, Won JH, Hong DS. Ji YS, et al. Korean J Intern Med. 2016 Jul;31(4):750-61. doi: 10.3904/kjim.2015.234. Epub 2016 Mar 28. Korean J Intern Med. 2016. PMID: 27017944 Free PMC article. - Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN. Lee KH, et al. Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25. Biol Blood Marrow Transplant. 2017. PMID: 28552421 Clinical Trial. - Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA. Russell JA, et al. Biol Blood Marrow Transplant. 2008 Aug;14(8):888-95. doi: 10.1016/j.bbmt.2008.05.010. Biol Blood Marrow Transplant. 2008. PMID: 18640572 Clinical Trial. - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review. - Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF. Khouri IF. Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658623 Free PMC article. Review.
Cited by
- Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
Huang XB, Yang X, Li CL, Zhang R, Wang W, Huang JW, Ye XM, Wang Y, Mao Y, Pu WQ, Zhou Y. Huang XB, et al. Bone Marrow Transplant. 2024 Oct 14. doi: 10.1038/s41409-024-02433-w. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39402188 - Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
Cavallaro G, Grassi A, Pavoni C, Micò MC, Busca A, Cavattoni IM, Santarone S, Borghero C, Olivieri A, Milone G, Chiusolo P, Musto P, Saccardi R, Patriarca F, Pane F, Saporiti G, Rivela P, Terruzzi E, Cerretti R, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Bernasconi P, Iori AP, Castagna L, Mordini N, Oldani E, Di Grazia C, Bacigalupo A, Rambaldi A. Cavallaro G, et al. Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5. Blood Cancer J. 2024. PMID: 39168989 Free PMC article. Clinical Trial. - Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Yeh AC, O'Donnell PV, Schoch G, Martin PJ, McFarland C, McCune JS, Cooper JP, Doney K, Flowers MED, Sorror ML, Appelbaum FR, Storer BE, Gooley T, Deeg HJ. Yeh AC, et al. Bone Marrow Transplant. 2022 Feb;57(2):198-206. doi: 10.1038/s41409-021-01518-0. Epub 2021 Nov 5. Bone Marrow Transplant. 2022. PMID: 34741096 Free PMC article. - Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.
Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT). Saraceni F, et al. Oncotarget. 2017 Dec 15;9(3):3379-3393. doi: 10.18632/oncotarget.23273. eCollection 2018 Jan 9. Oncotarget. 2017. PMID: 29423053 Free PMC article. - Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.
Altouri S, Sabloff M, Allan D, Atkins H, Huebsch L, Maze D, Samant R, Bredeson C. Altouri S, et al. Case Rep Hematol. 2016;2016:1257679. doi: 10.1155/2016/1257679. Epub 2016 Nov 13. Case Rep Hematol. 2016. PMID: 27957357 Free PMC article.
References
- Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817–2824. - PubMed
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763. - PubMed
- Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–9393. - PubMed
- Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous